News
Did Eli Lilly Just Say Checkmate to Novo Nordisk?
Novo Nordisk (NYSE: NVO) has seen revenue soar in recent years thanks to two drugs that have helped people around the world lose weight. The molecule is semaglutide, and it's sold under the name Ozempic for type 2 diabetes and Wegovy for weight loss -- but doctors have prescribed either for weight management.
Suspicious Ozempic products should be reported to Novo Nordisk or directly to the FDA. In addition, any adverse effects from ...
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...
In a move which could shake up the diabetes market, Novo Nordisk is discontinuing the country’s largest selling insulin, ...
Zacks Investment Research on MSN12h
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should KnowNovo Nordisk (NVO) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some ...
A unique Novo Nordisk legal challenge to the Medicare drug pricing program could have big implications for the pharma ...
Danish drugmaker Novo Nordisk said several hundred counterfeit units of its diabetes drug Ozempic were being distributed in ...
Novo Nordisk's stocks face YTD struggles due to trial results and tariffs, but strong fundamentals and outlook justify a Buy.
The FDA had rejected the companies’ initial application in 2023, requesting additional data after the pharma firms reported ...
Guggenheim’s Seamus Fernandez cut his rating on Novo Nordisk stock to Hold from Buy on Thursday, as did Evan David Seigerman ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback